Skip to main content
SpringerLink
Log in

Transgender and Migraine

  • Chapter
  • First Online:
Gender and Migraine

Part of the book series: Headache ((HEAD))

Abstract

Migraine is known to be affected by sex hormones, with the higher prevalence in women during the reproductive years considered to be due to the effects of oestrogen. Hence, migraine is likely to be affected by hormones used for transgender treatment. Of the very limited data available, the prevalence of migraine increases in transgender women using oestrogen and reduces in transgender men using testosterone. The increased prevalence of migraine aura in transgender women may be associated with high oestrogen dosing, particularly of oral oestrogen. Risks can be reduced by using transdermal hormones, which result in stable physiologic levels. In patients with aura, modifiable risk factors for stroke should be managed, particularly smoking cessation. Otherwise migraine management should follow national guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903.

    Article  PubMed  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.

    Book  Google Scholar 

  3. Collin L, Reisner SL, Tangpricha V, Goodman M. Prevalence of transgender depends on the “case” definition: a systematic review. J Sex Med. 2016;13(4):613–26.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, et al. Transgender people: health at the margins of society. Lancet. 2016;388(10042):390–400.

    Article  PubMed  Google Scholar 

  5. Gender Identity Development Service. Accessed on 18 Jan 2018. Available from: http://gids.nhs.uk/number-referrals.

  6. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87.

    Article  CAS  PubMed  Google Scholar 

  7. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3(6):354–61.

    Article  CAS  PubMed  Google Scholar 

  8. Pringsheim T, Gooren L. Migraine prevalence in male to female transsexuals on hormone therapy. Neurology. 2004;63(3):593–4.

    Article  PubMed  Google Scholar 

  9. Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology. 1999;53(3):537–42.

    Article  CAS  PubMed  Google Scholar 

  10. Aloisi AM, Bachiocco V, Costantino A, Stefani R, Ceccarelli I, Bertaccini A, et al. Cross-sex hormone administration changes pain in transsexual women and men. Pain. 2007;132(Suppl 1):S60–7.

    Article  CAS  PubMed  Google Scholar 

  11. World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people. 2011. Accessed on 18 Jan 2018. Available from: https://s3.amazonaws.com/amo_hub_content/Association140/files/Standards%20of%20Care%20V7%20-%202011%20WPATH%20(2)(1).pdf.

  12. Sanchez NF, Sanchez JP, Danoff A. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health. 2009;99(4):713–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mepham N, Bouman WP, Arcelus J, Hayter M, Wylie KR. People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge. J Sex Med. 2014;11(12):2995–3001.

    Article  PubMed  Google Scholar 

  14. de Haan G, Santos GM, Arayasirikul S, Raymond HF. Non-prescribed hormone use and barriers to care for transgender women in San Francisco. LGBT Health. 2015;2(4):313–23.

    Article  PubMed  Google Scholar 

  15. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2005;113(10):586–92.

    Article  CAS  PubMed  Google Scholar 

  16. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164(4):635–42.

    Article  CAS  PubMed  Google Scholar 

  17. Ho JY, Chen MJ, Sheu WH, Yi YC, Tsai AC, Guu HF, et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod. 2006;21(10):2715–20.

    Article  CAS  PubMed  Google Scholar 

  18. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–5.

    Article  CAS  PubMed  Google Scholar 

  19. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85(4):619–25.

    Article  CAS  PubMed  Google Scholar 

  20. Bergoglio MT, Gomez-Balaguer M, Almonacid Folch E, Hurtado Murillo F, Hernandez-Mijares A. Symptomatic meningioma induced by cross-sex hormone treatment in a male-to-female transsexual. Endocrinol Nutr. 2013;60(5):264–7.

    Article  PubMed  Google Scholar 

  21. Goh HH, Li XF, Ratnam SS. Effects of cross-gender steroid hormone treatment on prolactin concentrations in humans. Gynecol Endocrinol. 1992;6(2):113–7.

    Article  CAS  PubMed  Google Scholar 

  22. Bradshaw HB, Berkley KJ. The influence of ovariectomy with or without estrogen replacement on responses of rat gracile nucleus neurons to stimulation of hindquarter skin and pelvic viscera. Brain Res. 2003;986(1-2):82–90.

    Article  CAS  PubMed  Google Scholar 

  23. Gupta S, Villalon CM, Mehrotra S, de Vries R, Garrelds IM, Saxena PR, et al. Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. Headache. 2007;47(2):225–35.

    Article  PubMed  Google Scholar 

  24. Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, Baum MJ, et al. Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest. 2009;119(1):99–109.

    CAS  PubMed  Google Scholar 

  25. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13(3):177–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gazerani P, et al. Pain. 2005;118:155–63.

    Article  CAS  PubMed  Google Scholar 

  27. Ibrahimi K, et al. Neurology. 2015;84(2):125–31.

    Article  PubMed  Google Scholar 

  28. Labastida-Ramirez A, Rubio-Beltran E, Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2017.; 333102417739584.

    Google Scholar 

  29. Puri V, Cui L, Liverman CS, Roby KF, Klein RM, Welch KMA, et al. Ovarian steroids regulate neuropeptides in the trigeminal ganglion. Neuropeptides. 2005;39(4):409–17.

    Article  CAS  PubMed  Google Scholar 

  30. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Labruijere S, van Houten EL, de Vries R, Musterd-Bagghoe UM, Garrelds IM, Kramer P, et al. Analysis of the vascular responses in a murine model of polycystic ovary syndrome. J Endocrinol. 2013;218(2):205–13.

    Article  CAS  PubMed  Google Scholar 

  32. Valenti S, Fazzuoli L, Giusti M. Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexuals. J Endocrinol Invest. 2003;26(6):522–6.

    Article  CAS  PubMed  Google Scholar 

  33. New G, Duffy SJ, Harper RW, Meredith IT. Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males. Clin Exp Pharmacol Physiol. 2000;27(1-2):25–33.

    Article  CAS  PubMed  Google Scholar 

  34. Stanzani Maserati M. Migraine attacks, aura, and polycythemia: a vasculoneural pathogenesis? J Neural Transm (Vienna). 2011;118(4):545–7.

    Article  Google Scholar 

  35. Michiels JJ, Berneman Z, Gadisseur A, Lam KH, De Raeve H, Schroyens W. Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. Acta Haematol. 2015;133(1):56–63.

    Article  CAS  PubMed  Google Scholar 

  36. Cairns BE, Gazerani P. Sex-related differences in pain. Maturitas. 2009;63(4):292–6.

    Article  CAS  PubMed  Google Scholar 

  37. Gupta S, McCarson KE, Welch KM, Berman NE. Mechanisms of pain modulation by sex hormones in migraine. Headache. 2011;51(6):905–22.

    Article  PubMed  Google Scholar 

  38. Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res. 1999;105(1):53–68.

    Article  CAS  PubMed  Google Scholar 

  39. Eikermann-Haerter K, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C. Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Ann Neurol. 2009;66(4):564–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lichten EM, Bennett RS, Whitty AJ, Daoud Y. Efficacy of danazol in the control of hormonal migraine. J Reprod Med. 1991;36(6):419–24.

    CAS  PubMed  Google Scholar 

  41. Glaser R, Dimitrakakis C, Trimble N, Martin V. Testosterone pellet implants and migraine headaches: a pilot study. Maturitas. 2012;71(4):385–8.

    Article  CAS  PubMed  Google Scholar 

  42. Merki-Feld GS, Imthurn B, Langner R, Seifert B, Gantenbein AR. Positive effects of the progestin desogestrel 75 mg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days. J Headache Pain. 2015;16:522.

    Article  CAS  PubMed  Google Scholar 

  43. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

    Article  Google Scholar 

  44. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology. 2003;61(3):375–82.

    Article  CAS  PubMed  Google Scholar 

  45. Dodick DW. Pearls: headache. Semin Neurol. 2010;30(1):74–81.

    Article  PubMed  Google Scholar 

  46. Blau JN. Migraine: theories of pathogenesis. Lancet. 1992;339(8803):1202–7.

    Article  CAS  PubMed  Google Scholar 

  47. Kurth T, Chabriat H, Bousser MG. Migraine and stroke: a complex association with clinical implications. Lancet Neurol. 2012;11(1):92–100.

    Article  PubMed  Google Scholar 

  48. Gervil M, Ulrich V, Olesen J, Russell M. Screening for migraine in the general population: validation of a simple questionnaire. Cephalalgia. 1998;18:342–8.

    Article  CAS  PubMed  Google Scholar 

  49. Kuhl H. Pharmacokinetics of oestrogen and progestogens. Maturitas. 1990;12:171–97.

    Article  CAS  PubMed  Google Scholar 

  50. MacGregor A. Estrogen replacement and migraine aura. Headache. 1999;39:674–8.

    Article  CAS  PubMed  Google Scholar 

  51. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22(4):355–65.

    Article  CAS  PubMed  Google Scholar 

  52. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women’s hormonal migraine: the depo-estradiol challenge test. Headache. 1996;36(6):367–71.

    Article  CAS  PubMed  Google Scholar 

  53. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47(3):337–42.

    Article  Google Scholar 

  54. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010;123(7):612–24.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330(7482):63–5.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Kurth T, Schurks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ. 2008;337:a636.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010;74(8):628–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Li L, Schulz UG, Kuker W, Rothwell PM, Oxford Vascular S. Age-specific association of migraine with cryptogenic TIA and stroke: population-based study. Neurology. 2015;85(17):1444–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Article  CAS  PubMed  Google Scholar 

  61. Clarke MP, Coughlin JR. Prevalence of smoking among the lesbian, gay, bisexual, transsexual, transgender and queer (LGBTTQ) subpopulations in Toronto--the Toronto Rainbow Tobacco Survey (TRTS). Can J Public Health. 2012;103(2):132–6.

    Article  PubMed  PubMed Central  Google Scholar 

  62. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112–23.

    Article  PubMed  Google Scholar 

  63. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. Neurology. 2005;64(4):614–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Barts Health NHS Trust, London, UK

    E. Anne MacGregor

  2. Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

    Antoinette Maassen van den Brink

Authors
  1. E. Anne MacGregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoinette Maassen van den Brink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Anne MacGregor .

Editor information

Editors and Affiliations

  1. Division of Pharmacology and Vascular Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands

    Antoinette Maassen van den Brink

  2. Barts Health NHS Trust, London, UK

    E. Anne MacGregor

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

MacGregor, E.A., van den Brink, A.M. (2019). Transgender and Migraine. In: Maassen van den Brink, A., MacGregor, E. (eds) Gender and Migraine. Headache. Springer, Cham. https://doi.org/10.1007/978-3-030-02988-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02988-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02987-6

  • Online ISBN: 978-3-030-02988-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation